Spinocerebellar Ataxia Type 3Symptoms, Doctors, Treatments, Advances & More
Spinocerebellar Ataxia Type 3 Overview
Learn About Spinocerebellar Ataxia Type 3
View Main Condition: Movement Disorders
- Spinocerebellar ataxia 3
- Azorean neurologic disease
- MJD
- Machado-Joseph disease
- Nigrospinodentatal degeneration
- SCA3
- Spinocerebellar atrophy type 3
- Spinopontine atrophy
East Ann Arbor Health & Geriatrics Center
Henry Paulson is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Paulson is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia Type 3. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is board certified in Neurology. Dr. Paulson is currently accepting new patients.
Patricia Maciel practices practicing medicine in Gualtar, Portugal. Ms. Maciel is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 3. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Spinocerebellar Ataxia Type 3, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Striatonigral Degeneration Infantile.
Jose Pedroso practices practicing medicine in Vila Clementino, Brazil. Mr. Pedroso is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 3. He is also highly rated in 49 other conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, Spinocerebellar Ataxia Type 3, and Drug Induced Dyskinesia.
Summary: The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts. Through par...
Summary: The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be admini...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center
